Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2

CT-322 is a new anti-angiogenic therapeutic agent based on an engineered variant of the tenth type III domain of human fibronectin, i.e., an Adnectin™, designed to inhibit vascular endothelial growth factor receptor (VEGFR)-2. This PE Gylated Adnectin was developed using an mRNA display technology....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mamluk, Roni, Carvajal, Irvith M, Morse, Brent A, Wong, Henry, Abramowitz, Janette, Aslanian, Sharon, Lim, Ai-Ching, Gokemeijer, Jochem, Storek, Michael J, Lee, Joonsoo, Gosselin, Michael, Wright, Martin C, Camphausen, Ray T, Wang, Jack, Chen, Yan, Miller, Kathy, Sanders, Kerry, Short, Sarah, Sperinde, Jeff, prasad, Gargi, Williams, Stephen, Kerbel, Robert, ebos, John, Mutsaers, Anthony, Mendlein, John D, Harris, Alan S, Furfine, Eric S
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2010
Assuntos:
Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2840239/
https://ncbi.nlm.nih.gov/pubmed/20190562
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados